BR112020015308A8 - Proteínas f de rsv estabilizadas e usos das mesmas - Google Patents

Proteínas f de rsv estabilizadas e usos das mesmas

Info

Publication number
BR112020015308A8
BR112020015308A8 BR112020015308A BR112020015308A BR112020015308A8 BR 112020015308 A8 BR112020015308 A8 BR 112020015308A8 BR 112020015308 A BR112020015308 A BR 112020015308A BR 112020015308 A BR112020015308 A BR 112020015308A BR 112020015308 A8 BR112020015308 A8 BR 112020015308A8
Authority
BR
Brazil
Prior art keywords
proteins
rsv
stabilized rsv
stabilized
immunogenic compositions
Prior art date
Application number
BR112020015308A
Other languages
English (en)
Other versions
BR112020015308A2 (pt
Inventor
Zhang Lan
Fridman Arthur
Durr Eberhard
Bett Andrew
Original Assignee
Merck Sharp & Dohme
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme
Publication of BR112020015308A2 publication Critical patent/BR112020015308A2/pt
Publication of BR112020015308A8 publication Critical patent/BR112020015308A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

A invenção se refere a proteínas F de RSV estáveis e composições imunogênicas contendo as mesmas, bem como a métodos de usar as composições imunogênicas e composições compreendendo as proteínas F de RSV.
BR112020015308A 2018-01-29 2019-01-24 Proteínas f de rsv estabilizadas e usos das mesmas BR112020015308A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862623184P 2018-01-29 2018-01-29
US62/623,184 2018-01-29
PCT/US2019/014873 WO2019147749A2 (en) 2018-01-29 2019-01-24 Stabilized rsv f proteins and uses thereof

Publications (2)

Publication Number Publication Date
BR112020015308A2 BR112020015308A2 (pt) 2020-12-08
BR112020015308A8 true BR112020015308A8 (pt) 2023-02-07

Family

ID=67396243

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020015308A BR112020015308A8 (pt) 2018-01-29 2019-01-24 Proteínas f de rsv estabilizadas e usos das mesmas

Country Status (11)

Country Link
US (2) US11566051B2 (pt)
EP (1) EP3746462A4 (pt)
JP (1) JP2021511356A (pt)
KR (1) KR20200115567A (pt)
CN (1) CN111655715A (pt)
AU (1) AU2019212237A1 (pt)
BR (1) BR112020015308A8 (pt)
CA (1) CA3088546A1 (pt)
MA (1) MA51230A (pt)
MX (1) MX2020007945A (pt)
WO (1) WO2019147749A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3200234A1 (en) 2020-11-25 2022-06-02 Daryl C. Drummond Lipid nanoparticles for delivery of nucleic acids, and related methods of use
WO2022169835A1 (en) * 2021-02-03 2022-08-11 The Board Of Trustees Of The University Of Illinois Vaccine and methods for preventing filariasis and dirofilariasis
CN113577258B (zh) * 2021-07-31 2024-04-16 山东兴瑞生物科技有限公司 一种双靶点mRNA疫苗及其制备方法
CN117715923A (zh) * 2022-04-29 2024-03-15 北京新合睿恩生物医疗科技有限公司 Rsv f蛋白突变体及其应用
WO2024078597A1 (en) * 2022-10-13 2024-04-18 Rvac Medicines (Us) , Inc. Rsv f protein variants and uses thereof
CN116478296B (zh) * 2022-10-17 2024-02-23 厦门大学 截短的呼吸道合胞病毒f蛋白及其用途
CN117586359A (zh) * 2024-01-19 2024-02-23 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽
CN117567652B (zh) * 2024-01-19 2024-05-14 北京安百胜生物科技有限公司 一种重组呼吸道合胞病毒颗粒抗原

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US6287591B1 (en) 1997-05-14 2001-09-11 Inex Pharmaceuticals Corp. Charged therapeutic agents encapsulated in lipid particles containing four lipid components
US20030077829A1 (en) 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
TW200501985A (en) * 2002-07-25 2005-01-16 Medimmune Inc Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
ATE471335T1 (de) 2002-12-23 2010-07-15 Vical Inc Impfstoffe gegen infektionen mit dem humanen zytomegalivirus auf grundlage von codonoptimierten polynukleotiden
AU2004272646B2 (en) 2003-09-15 2011-11-24 Arbutus Biopharma Corporation Polyethyleneglycol-modified lipid compounds and uses thereof
WO2005116270A2 (en) 2004-05-18 2005-12-08 Vical Incorporated Influenza virus vaccine composition and method of use
WO2007086883A2 (en) 2005-02-14 2007-08-02 Sirna Therapeutics, Inc. Cationic lipids and formulated molecular compositions containing them
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
WO2009132131A1 (en) 2008-04-22 2009-10-29 Alnylam Pharmaceuticals, Inc. Amino lipid based improved lipid formulation
US20110224447A1 (en) 2008-08-18 2011-09-15 Bowman Keith A Novel Lipid Nanoparticles and Novel Components for Delivery of Nucleic Acids
ES2475065T3 (es) 2008-10-09 2014-07-10 Tekmira Pharmaceuticals Corporation Aminol�pidos mejorados y métodos para la administración de ácidos nucleicos
EP2406376A1 (en) 2009-03-12 2012-01-18 Alnylam Pharmaceuticals, Inc. LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
CN102460553B (zh) 2009-06-17 2014-04-16 夏普株式会社 显示驱动电路、显示装置和显示驱动方法
DK3178490T3 (da) 2009-07-15 2022-06-20 Glaxosmithkline Biologicals Sa RSV F-proteinsammensætninger og fremgangsmåder til fremstilling af disse
EP2467357B1 (en) 2009-08-20 2016-03-30 Sirna Therapeutics, Inc. Novel cationic lipids with various head groups for oligonucleotide delivery
US20110200582A1 (en) 2009-12-23 2011-08-18 Novartis Ag Lipids, lipid compositions, and methods of using them
JP5961170B2 (ja) 2010-09-20 2016-08-02 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． オリゴヌクレオチドの送達のための新規な低分子量カチオン性脂質
EP2782594B1 (en) 2011-11-23 2019-04-17 Merck Sharp & Dohme Corp. Method for preparation of aluminum hydroxyphosphate adjuvant
EP2970398B1 (en) 2013-03-13 2024-05-08 The United States of America, as Represented by The Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
WO2015130584A2 (en) * 2014-02-25 2015-09-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
HRP20220156T1 (hr) 2015-09-17 2022-04-15 Modernatx, Inc. Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
JP7384512B2 (ja) * 2015-10-22 2023-11-21 モデルナティエックス インコーポレイテッド 広域インフルエンザウイルスワクチン
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
PE20181354A1 (es) * 2015-12-23 2018-08-22 Pfizer Mutantes de proteina f de rsv
CN115960263A (zh) * 2016-03-29 2023-04-14 美国政府(由卫生和人类服务部的部长所代表) 取代修饰的融合前rsv f蛋白及其用途

Also Published As

Publication number Publication date
AU2019212237A1 (en) 2020-07-30
RU2020128445A3 (pt) 2022-02-28
US11566051B2 (en) 2023-01-31
BR112020015308A2 (pt) 2020-12-08
RU2020128445A (ru) 2022-02-28
MX2020007945A (es) 2020-09-24
MA51230A (fr) 2021-05-05
EP3746462A2 (en) 2020-12-09
US20210300971A1 (en) 2021-09-30
US20230141153A1 (en) 2023-05-11
CA3088546A1 (en) 2019-08-01
WO2019147749A3 (en) 2019-09-19
CN111655715A (zh) 2020-09-11
KR20200115567A (ko) 2020-10-07
WO2019147749A2 (en) 2019-08-01
EP3746462A4 (en) 2022-01-05
JP2021511356A (ja) 2021-05-06

Similar Documents

Publication Publication Date Title
BR112020015308A8 (pt) Proteínas f de rsv estabilizadas e usos das mesmas
MD3370770T2 (ro) Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
EA201890058A1 (ru) Производное глюкагона и композиция, содержащая длительно действующий конъюгат этого производного
CR20140200A (es) Formas solidas de 3-(5-amino-2-metil-4-oxo-ah-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y sus usos
CO2017000064A2 (es) Compuestos de [1,2,4]triazol sustituido
EA201992610A1 (ru) Экспансия -t-клеток, композиции и способы их применения
CL2019000640A1 (es) Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y métodos de uso.
CO2019009787A2 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos
ECSP17029287A (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
EA201890572A1 (ru) Биофармацевтические композиции
EA201991798A1 (ru) Стабильные при хранении составы
BR112018001017A2 (pt) inibidores do receptor de fator-1 de estimulação de colônia (csf-1r)
CR20170008A (es) Compuestos de [1,2,4] triazol e imidazol sustituidos
CY1121187T1 (el) Ενα εκχυλισμα απο indigo naturalis και μια διεργασια για την παρασκευη εκεινου
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
CO2021011906A2 (es) Anticuerpos claudina 6 y usos de los mismos
BR112018009264A2 (pt) composições para cuidados de animais de estimação
EA202092695A1 (ru) Композиции, содержащие глюкозу и гемицеллюлозу, и их применение
EA202090732A1 (ru) Составы для трансдермального введения
BR112021025317A2 (pt) Tienilhidroxiisoxazolinas e derivados das mesmas
MX2019010009A (es) Composiciones para el cuidado personal.
EA201791716A1 (ru) Фармацевтический состав
MX2018006525A (es) Gel para el cuidado bucal.
PH12017501869A1 (en) (s)-2'-vinyl-abscisic acid derivatives

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: MERCK SHARP AND DOHME LLC (US)